

Taro Pharmaceuticals USA, Inc.  
BALANCE SHEET

	March 31, 2023	March 31, 2022
	US Dollars	
	Unaudited	
<b>ASSETS</b>		
<b>CURRENT ASSETS</b>		
Cash	\$ 25,049,571	\$ 19,225,399
Marketable Securities	239,703	-
Trade/Open Accounts+Ch.Rec.	152,060,420	181,240,951
<b>Other receivables and prepaid expense:</b>		
Accounts Receivable - Other	10,454,104	11,946,262
Deferred Taxes	-	-
Corporate Taxes Receivable	15,721,614	17,733,577
<b>Total Other receivables and prepaid expense:</b>	<b>26,175,718</b>	<b>29,679,839</b>
Inventories	83,118,731	97,672,659
<b>TOTAL CURRENT ASSETS</b>	<b>286,644,143</b>	<b>327,818,848</b>
<b>LONG-TERM RECEIVABLES AND OTHER ASSETS</b>		
Goodwill	10,040,307	-
Long term investments	1,370,092	1,414,057
Long term marketable securities	7,149,676	8,532,819
<b>FIXED ASSETS</b>		
Cost	68,013,817	66,827,115
Less-Accum.Depreciation	(38,969,943)	(35,636,220)
	29,043,874	31,190,895
<b>INTANGIBLE ASSETS AND DEFERRED COSTS, NET</b>		
INTANGIBLE ASSETS AND DEFERRED COSTS, NET	59,873,333	-
OTHER ASSETS	54,984,631	147,478,177
<b>TOTAL ASSETS</b>	<b>\$ 449,106,056</b>	<b>\$ 516,434,796</b>

Taro Pharmaceuticals USA, Inc.  
BALANCE SHEET

	March 31, 2023	March 31, 2022
	US Dollars	
	Unaudited	
<b>LIABILITIES AND SHAREHOLDERS' EQUITY</b>		
<b>CURRENT LIABILITIES</b>		
Current maturities of lt.liab.	\$ -	\$ -
Accounts payable: Suppliers	5,335,389	4,914,671
<b>Other current liabilities:</b>		
Returns reserve	-	-
Intercompany Payables	342,671,720	321,436,361
Employees and payroll accruals	-	-
Legal and audit fees	-	-
Settlements and loss contingencies	-	-
Accrued Expenses Payable - Others	210,567,185	280,147,013
Taxes Payable	-	-
<b>TOTAL Other current liabilities</b>	<b>553,238,905</b>	<b>606,498,046</b>
Long term liabilities	-	-
SWAP	-	-
Deferred Taxes	-	-
Amount Accrued/ Other long term	2,950,001	1,475,002
<b>TOTAL LONG TERM LIABILITIES</b>	<b>2,950,001</b>	<b>1,475,002</b>
<b>SHAREHOLDERS' EQUITY</b>	<b>(112,418,238)</b>	<b>(91,538,252)</b>
<b>TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</b>	<b>\$ 449,106,056</b>	<b>\$ 516,434,796</b>

Date of approval of the financial statements

VP, Chief Financial Officer

Taro Pharmaceuticals USA, Inc.  
STATEMENTS OF OPERATIONS

	For the Year Ended	
	March 31, 2023	March 31, 2022
	US Dollars	
Unaudited		
<b>Sales - Income</b>	<b>\$ 278,648,786</b>	<b>\$ 361,158,879</b>
Cost of Sales	211,288,401	295,459,278
Cost of Sales Impairment	-	-
<b>Gross Profit</b>	<b>67,360,385</b>	<b>65,699,601</b>
Research & Development	2,041,078	1,636,169
Selling and Marketing Expenses	25,862,482	26,622,188
General and Administrative Expenses	30,781,327	31,811,098
Settlements and loss contingencies	-	10,025,629
<b>Operating Income</b>	<b>8,675,498</b>	<b>(4,395,483)</b>
Financial Expenses	5,157,177	5,085,906
Other Income	36,296,242	(1,414,098)
<b>Income before taxes on Income</b>	<b>(32,777,921)</b>	<b>(8,067,291)</b>
Taxes on Income	(6,423,824)	(5,769,761)
<b>Net (loss) income for the period</b>	<b>\$ (26,354,097)</b>	<b>\$ (2,297,530)</b>

Taro Pharmaceuticals USA, Inc.  
STATEMENTS OF COMPREHENSIVE INCOME

	For the Year Ended	
	March 31, 2023	March 31, 2022
	US Dollars	
Unaudited		
<b>Net (loss) income</b>	<b>\$ (26,354,097)</b>	<b>\$ (2,297,530)</b>
Loss from marketable securities	-	-
<b>Total other comprehensive loss</b>	<b>-</b>	<b>-</b>
<b>Total comprehensive (loss) income</b>	<b>\$ (26,354,097)</b>	<b>\$ (2,297,530)</b>

Taro Pharmaceuticals USA, Inc.  
STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY

	Share capital	Additional Paid in Capital	Accumulated Other Comprehensive (Loss) Income	Retained Earnings	Total Shareholders' Equity
	US Dollars				
	Unaudited				
<b>Balance as of March 31, 2016</b>	\$ 145,000	\$ 8,278,828	\$ 194,347	\$ (10,535,985)	\$ (1,917,810)
Loss on available for sale marketable securities	-	-	(69,307)	-	(69,307)
Net income	-	-	-	9,906,327	9,906,327
<b>Balance as of March 31, 2017</b>	145,000	8,278,828	125,040	(629,658)	7,919,210
Loss on available for sale marketable securities	-	-	(125,040)	-	(125,040)
Net income	-	-	-	(34,294,912)	(34,294,912)
<b>Balance as of March 31, 2018</b>	\$ 145,000	\$ 8,278,828	\$ -	\$ (34,924,570)	\$ (26,500,742)
Net income	-	-	-	11,052,721	11,052,721
<b>Balance as of March 31, 2019</b>	\$ 145,000	\$ 8,278,828	\$ -	\$ (23,871,849)	\$ (15,448,021)
Unrealized gains (losses) on available for sale marketable securities	-	-	(285,782)	-	(285,782)
Net income	-	-	-	9,895,542	9,895,542
<b>Balance as of March 31, 2020</b>	145,000	8,278,828	(285,782)	(13,976,307)	(5,838,261)
Unrealized gains (losses) on available for sale marketable securities	-	-	287,155	-	287,155
Net income	-	-	-	(450,773,212)	(450,773,212)
<b>Balance as of March 31, 2021</b>	145,000	8,278,828	1,373	(464,749,519)	(456,324,318)
Unrealized gains (losses) on available for sale marketable securities	-	-	(34,175)	-	(34,175)
Capital Contribution (Premium)	-	367,117,778	-	-	367,117,778
Net income	-	-	-	(2,297,530)	(2,297,530)
<b>Balance as of March 31, 2022</b>	145,000	375,396,606	(32,802)	(467,047,049)	(91,538,245)
Unrealized gains (losses) on available for sale marketable securities	-	-	(7,985)	-	(7,985)
Capital Contribution (Premium)	-	5,482,222	-	-	5,482,222
Net income	-	-	-	(26,354,097)	(26,354,097)
<b>Balance as of March 31, 2023</b>	145,000	380,878,828	(40,787)	(493,401,146)	(112,418,105)